/Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

NEWS

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

PRNewswire

2025/01/06

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease News provided by Sentynl Therapeutics Jan 06, 2025, 08:00 ET Share this article Share to X Share this article Share to X Sentynl Therapeutics, Inc. (PRNewsfoto/Sentynl Therapeutics) Zydus (PRNewsfoto/Sentynl Therapeutics)

Summary

/PRNewswire/ -- Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group"), and...